Skip to main content
Signal8

CDT Commences Human Skin Studies with QIMA Life Sciences on Novel Tapinarof Combinations in Vitiligo

$CDTPress releaseNov 11, 2026, 7:00 AM ETRead the release

CDT Equity has commenced human skin studies with QIMA Life Sciences evaluating its proprietary tapinarof combinations in vitiligo, formally kicking off the partnership announced September 18, 2026. The studies use human skin from healthy donors and patients to generate preclinical data in the most physiologically relevant setting available, which CDT says will underpin the licensing data package for out-licensing the combinations.

Key figures

Drug Name
tapinarof combinations
Vitiligo prevalence
0.5%-2.0%
Vitiligo market 2025 usd
$2.6 billion
Vitiligo market 2030 projected usd
$6.6 billion

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.